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Abstract
Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity lung disease mediated by an allergic late-phase
inflammatory response to Aspergillus fumigatus antigens. ABPA is characterized by markedly elevated Aspergillus-specific and
total IgE levels and eosinophilia, and manifested by wheezing, pulmonary infiltrates, and bronchiectasis and fibrosis, which afflict
asthmatic and cystic fibrosis (CF) patients. We propose that ABPA develops in genetically susceptible CF patients due to HLA-
DR2 and DR5 restriction, increased sensitivity to IL-4 stimulation, and increased A. fumigatus allergen-specific Th2 CD4q T-
cell-mediated responses. In addition, A. fumigatus proteases play a role in facilitation of antigen transport across the epithelial cell
layer by damaging the epithelial integrity and by a direct interaction with epithelial cell surface receptors, resulting in pro-
inflammatory cytokine production and corresponding inflammatory responses.  2002 European Cystic Fibrosis Society. Published
by Elsevier Science B.V. All rights reserved.
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1. Introduction
Allergic bronchopulmonary aspergillosis (ABPA) is a
hypersensitivity lung disease mediated by an allergic
late-phase inflammatory response to certain Aspergillus
fumigatus antigens that occurs in approximately 1–2%
of asthmatic and 7–10% of cystic fibrosis patients w1–
16x. ABPA is characterized by markedly elevated Asper-
gillus-specific IgE and total IgE levels and eosinophilia,
and manifested by wheezing, pulmonary infiltrates,
bronchiectasis and fibrosis. The immune response to
Aspergillus antigens in ABPA, as well as in allergic
asthmatic and cystic fibrosis patients, is characterized
by a Th2 CD4q T-cell response w1x. A central question
then is how ABPA differs from Aspergillus-sensitive
atopic asthmatic and CF patients. It is proposed that
ABPA develops in genetically susceptible cystic fibrosis
patients due to increased frequency andyor activity of
Aspergillus-specific Th2 CD4q T cells and to HLA-
DR restriction. In addition, Aspergillus proteases damage
the respiratory epithelial barrier, exposing the bronchoal-
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veolar lymphoid tissue (BALT) to high concentrations
of Aspergillus antigens that alter the immune response.
The allergic inflammatory response in ABPA appears
to be quantitatively greater than in Aspergillus-sensitive
cystic fibrosis patients. In the model proposed of the
immunopathogenesis of ABPA, as illustrated in Fig. 1,
A. fumigatus spores are inhaled into the bronchial airway,
where they are trapped by the luminal mucus, germinate
and form mycelia. A. fumigatus mycelia release allergens
that are processed by antigen-presenting cells (APC)
bearing HLA-DR2 or DR5 and presented to T-cells
within the bronchoalveolar lymphoid tissue (BALT).
The T-cell response to Aspergillus allergens becomes
skewed toward a Th2 CD4q T-cell response with IL-4,
IL-5 and IL-13 cytokine synthesis and secretion.
2. Interaction of respiratory epithelium and
Aspergillus
One of the characteristics features in patients with
ABPA is the observations that A. fumigatus is found
bound to the surface epithelium growing on and between
the epithelial cells without being efficiently killed by
mononuclear cells and eosinophils w17x. It has also been
shown that spores of A. fumigatus are attached to
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Fig. 1. Model of pathogenesis of allergic bronchopulmonary aspergillosis (from Knutsen et al. w1x).
epithelial surfaces cultured in vitro w18x. The physical
presence of A. fumigatus is possibly of importance for
the modulation of the immunological response towards
a Th2-type response w19x. In order to evade the very
effective natural defense system of the human airways
against fungi, various virulence factors of A. fumigatus
have been detected that have been shown to interfere
with, or even block, normal functions of the humoral
and cellular defense of the airways w20,21x. Some of
these virulence factors are the proteolytic enzymes of A.
fumigatus, which facilitate the immune response to the
fungal antigens and play a role in the inflammatory
response.
2.1. Aspergillus proteolytic enzymes
It has been found that certain strains of A. fumigatus
release proteolytic enzymes with elastolytic and colla-
genolytic activity. The possible role of these proteolytic
enzymes as a pathogenic factor in fatal invasive asper-
gillosis is still uncertain. However, findings in patients
with ABPA or aspergilloma indicate that these proteases
may be involved in the pathogenesis of these diseases.
In studies of ABPA, culture filtrate extracts with marked
elastase and collagenase activity were examined. In
Western blot experiments, binding of IgG antibodies to
a 32-kDa elastase protein was found with sera from
patients with ABPA or aspergilloma w22x. The pro-
nounced binding of IgG antibodies to the 32-kDa fungal
elastase suggests that these proteases are produced in
vivo in patients with ABPA and aspergilloma. Further-
more, during exacerbation of aspergilloma, antibody
concentrations against different antigens, including the
32- and 40-kDa proteases, were markedly increased
w23x. The observation that the antibody concentrations
against the 32- and 40-kDa fungal proteases are
increased during the exacerbation phase indicates that
these proteases may play a role in the pathogenicity of
the disease.
2.2. Aspergillus proteases and host cytokines
An important feature of pathogenic microorganisms
is their capacity to interact with epithelial cells of the
mucosal surface. Previously, it has been shown that
products released in vitro by A. fumigatus are able to
cause epithelial cell detachment w24,25x. This capacity
to induce epithelial cell detachment is also characteristic
of other proteases released by different fungi, e.g.
Alternaria and Cladosporium, but Aspergillus proteases
are more active at much lower concentrations w26x.
Recent studies performed with proteases from various
sources, e.g. Der p1 from house dust mite w27x, have
shown that degradation of epithelial cell structures
results in facilitated transport of antigens and allergens
across the epithelium, leading to enhanced exposure to
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antigen-presenting cells with concurrent immune
responses.
In addition to damaging the epithelial cell-layer integ-
rity, recent studies have shown that human bronchial
and alveolar epithelial cell lines produce pro-inflamma-
tory cytokines, such as IL-8, IL-6 and MCP-1, after
incubation with protease-containing culture filtrates of
A. fumigatus. This cytokine-releasing activity could be
ascribed to the proteolytic activity of these extracts w25x.
These observations suggest that proteolytic enzymes
released by Aspergillus growing on and between epithe-
lial cells may be responsible for the induction of
chemoattractive cytokines by epithelial cells and corre-
sponding inflammatory responses. It has been proposed
that induction of a severe inflammatory response by the
direct activation of epithelial cells may induce additional
epithelial injury w20x. Destruction of the epithelial cell
barrier by proteases from either the fungus, or from the
eosinophilic and neutrophilic inflammation, is followed
by repair mechanisms, resulting in the influx of serum
proteins and extracellular matrix proteins to the luminal
site of the epithelium w28x. Since spores and mycelia of
A. fumigatus have surface structures that are able to
interact with extracellular matrix molecules, damage and
concurrent repair of the airway mucosa, with simulta-
neous release of repair molecules, may facilitate the
binding of Aspergillus to the damaged sites of the
airways. The interaction of enhanced release of proteo-
lytic enzymes and allergens on the epithelial surface
will induce a continuous inflammatory response and
mast cell degranulation, resulting in severe and long-
lasting periods of exacerbation of ABPA.
In addition to the induction of cytokine responses of
epithelial cells, it was shown that proteases from A.
fumigatus at higher concentrations also inhibit epithelial
cell cytokine production w26x. This inhibition was spe-
cific for the elastaseycollagenase-containing extracts of
A. fumigatus, which may represent an additional viru-
lence factor by preventing effective targeting by infiltra-
tive phagocytic cells. This would lead to continuous
release of antigens and allergens, and strong activation
of the Th2-type immunological response, with very high
production of total and specific IgE antibody, as well as
an additional Th1 response, with the formation of IgG
and IgA antibodies to antigens of A. fumigatus, as is
observed in patients with ABPA.
3. Host immune responses to Aspergillus
The allergic inflammatory response in ABPA appears
to be quantitatively greater than in Aspergillus-sensitive
cystic fibrosis patients. In the model proposed of the
immunopathogenesis of ABPA (Fig. 1), A. fumigatus
spores are inhaled into the bronchial airway, where they
are trapped by the luminal mucus, germinate and form
mycelia. A. fumigatus mycelia release allergens that are
processed by antigen-presenting cells (APC) bearing
HLA-DR2 or DR5 and presented to T-cells within the
bronchoalveolar lymphoid tissue (BALT). The T-cell
response to Aspergillus allergens becomes skewed
toward a Th2 CD4q T-cell response, with IL-4, IL-5
and IL-13 cytokine synthesis and secretion.
3.1. Th2 CD4q T-cells in ABPA
Several groups have observed T-cell lymphoprolifer-
ative responses to crude Aspergillus extracts w29–32x.
Subsequently, Aspergillus-specific T-cell responses were
examined. In these studies, T-cells were stimulated with
a crude Aspergillus extract for 48 h, and the Aspergillus-
stimulated T-cell supernatant was then co-cultured with
atopic control B-cells for 10 days. These supernatants
obtained from Aspergillus-stimulated T-cells from ABPA
patients enhanced B-cell IgE synthesis w33x. Subsequent-
ly, T-cell lines were generated from ABPA patients with
an Aspergillus allergen, Asp f1 w34x. In these studies, T-
cell phenotype was exclusively CD4qCD25qHLA-
DRq T-cells (Table 1). The cytokine profile of these
T-cells was IL-4q, IFN-gy, i.e. Th2 CD4q T-cells.
Indeed, the lymphoproliferative stimulus for Asp f1 T-
cell lines was predominantly IL-4-mediated, i.e. an
autocrine pattern (Fig. 2). However, atopic Aspergillus-
sensitive CF patients also developed Th2 CD4q T-cells.
Subsequent studies performed by Chauhan and co-
workers w35,36x demonstrated that T-cell clones obtained
from asthmatic ABPA patients were either Th2 (IL-4q
, IFN-gy) or Th0 (IL-4q, IFN-gq) T-cells. Further-
more, tetanus toxoid-generated T-cell clones were the
expected Th1 phenotype, namely IFN-gq. Thus, the
Th2 CD4q T-cell response in ABPA is specific to
Aspergillus antigens, and not a generalized Th2 cell
response to all antigens.
3.2. IL-4 cytokine in ABPA
IL-4 plays a critical role in the allergic inflammatory
response in ABPA (Fig. 1). IL-4 up-regulates cellular
activity via binding to IL-4 receptor (IL-4R) found on
a variety of cells, including B-cells, NK-cells, mast
cells, endothelial cells and a subpopulation of T-cells
w37–42x. IL-4 and IL-13 induce IgE isotype switching
of B-cells w43–48x. Although IL-4 is necessary for IgE
isotype switching, it is not sufficient. In order for IgE
secretion to occur, a second signal mediated by cell–
cell T- and B-cell interactions via CD40L::CD40 and
CD28::CD86 ligand–receptor interactions occurs w46–
58x. IL-4 also induces the low-affinity IgE receptor
CD23 and soluble CD23, which augments B-cell IgE
synthesis w46,47,59–64x. In addition, T-cell CD23 and
B-cell CD21 cognate ligation also augments B-cell IgE
synthesis. CD86 expression on B-cells is also up-regu-
lated by IL-4 in atopic patients w49–57x. CD86 on B-
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Table 1
Asp f1 T-cell lines from patients with ABPA
Study Cystic fibrosis patients Asthmatic patients
1 2 3 4 1 2
Diagnosis of ABPA q q q Atopic q q
Serum IgE (IUyml) 3800 1950 2091 634 7000 450
Phenotype (%)a
CD3q 97 99 100 100 99 97
CD4q 100 99 98 100 100 100
CD8q 0 0 0 0 0 0
CD25q 96 99 97 97
DRq 91 100 97 95
TCRabq 99 99 100 99
CD45ROq 100 100
CD23qCD3q 1.3 0.7 1.3 1.6
Lymphoproliferationb
Asp f1 (cpm) 37481 16219 24481 57168 9644
(SI) (21.0) (3.3) (20.8) (4.3) (11.4)
Tetanus toxoid (cpm) y1137 1009 27 10712 278
(SI) (0.4) (0.4) (1.0) (1.6) (1.3)
Cytokine synthesis supernatantc
IL-4 (pgym)l 300 70000 6600 13800 16600
IFN-g (pgyml) -100 1200 -100 -100 -100
IL-2 (Uyml) ND ND -300 ND -300
From Knutsen et al. w34x.
Analyzed by flow cytometry using FITC or PE labeled monoclonal antibodies.a
For lymphoproliferation assay of Asp f1 T-cell lines, the cell lines were rested, then incubated with media, Asp f1 or tetanus toxoid for 72b
h. Counts per minute (cpm) are net cpm calculated as stimulated minus media.
For cytokine synthesis of Asp f1-stimulated T-cell lines, the cell lines were rested, then incubated with Asp f1 for 48 h.c
cells is an important co-stimulatory molecule for
augmentation of IgE synthesis. The ligand for CD86 is
CD28 on T-cells. In addition, several studies have
observed CD86 to be critical in promoting Th2 CD4q
T-cell responses and cytokine synthesis, eosinophil air-
way inflammation and airway hyperresponsiveness after
allergen challenge. Since ABPA is characterized by a
heightened Th2 CD4q T-cell response to A. fumigatus
allergens and a hyper-IgE state, it is hypothesized that
one reason for this response is increased sensitivity to
IL-4 stimulation in ABPA, resulting in increased expres-
sion of CD23 and CD86, leading to a positive feedback
amplification mechanism, which also increases Th2
CD4q T-cell responses. In recent studies, it was
observed that the B-cells from ABPA patients were
significantly more sensitive to IL-4 stimulation com-
pared to atopic and non-atopic patients, with up-regula-
tion of CD23 and CD86 expression w65x. Recently, it
was demonstrated that ABPA CF patients had signifi-
cantly increased rates of CD23 expression per B-cell to
IL-4, but not to IL-13 stimulation compared to non-
ABPA CF patients and non-atopic controls (Figs. 3 and
4) w66x. Furthermore, ABPA CF patients also had
significantly increased CD23 expression on CD86q B-
cells compared to non-ABPA CF and control patients
(Fig. 3). At day 0 prior to culture, the number of CD23
molecules per B-cell and CD86q B-cell were signifi-
cantly elevated in vivo in ABPA CF patients compared
to non-ABPA CF and to non-atopic patients (Fig. 3).
Thus, ABPA patients had increased sensitivity to IL-4,
but not IL-13 stimulation, with up-regulation of CD23
and CD86 expression compared to non-ABPA CF
patients and non-atopic controls, such that ABPA CF)
non-ABPA CF4non-atopic patients. We propose that
in ABPA there is a positive amplification feedback loop
mechanism of B-cell CD86 and Th2 CD4q T-cell IL-4
stimulation.
The model proposes that A. fumigatus growing within
the airways releases high levels of allergens in the
airway and lung parenchyma, which in turn produces a
heightened and prolonged late-phase allergic inflamma-
tory response. Furthermore, ABPA patients develop IgE
antibodies to specific Aspergillus proteins, Asp f2, Asp
f4 andyor Asp f6, whereas atopic patients develop IgE
antibodies to Asp f1 andyor Asp f3 w67–72x. It is
hypothesized that mycelial formation and secretion of
proteins in ABPA is necessary, suggesting that the
colonization in ABPA is greater than in Aspergillus-
sensitive atopic patients. This increased exposure to
Aspergillus allergens occurring in a genetically suscep-
tible host then drives the skewed Th2 CD4q T-cell and
hyper-IgE responses observed in ABPA. Recently, stud-
ies to determine whether there is increased frequency of
Th2 CD4q T-cells in patients with ABPA have been
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Fig. 2. Asp f1-specific T-cell line was rested for 2–17 days after IL-
2 and Asp f1 stimulation (top panel). Supernatant IL-4 concentration
was measured serially. Significant amounts of IL-4 were synthesized
for up to 10–14 days of rest. Monoclonal anti-IL-4 antibody inhibited
Asp f1-stimulated lymphoproliferation of antigen-specific T-cell lines
in a dose–response manner (bottom panel). Maximum inhibition was
84% at 5% anti-IL-4 antibody concentration (vyv) in this experiment
and 78% in a second experiment. Anti-IL-2 had little inhibition of
proliferation, indicating an IL-4-dependent autocrine lymphoprolifer-
ative response (from Knutsen et al. w34x).
initiated w66x. As observed in Fig. 5, the frequency of
cytoplasmic IFN-gq and IL-4q CD3q T cells in
PMA- and ionomycin-stimulated cultures was compa-
rable in CF patients with ABPA compared to non-ABPA
CF patients, indicating that there was not a skewing of
Th2 CD4q T-cell responses (Fig. 5a). Interestingly,
IFN-gq CD3q T-cells were significantly decreased in
both ABPA and non-ABPA CF patients compared to
non-atopic controls. When antigen-specific frequency of
Th1 and Th2 responses were evaluated, a different
picture emerged. The frequency of IFN-gq CD3q T-
cells in tetanus toxoid-stimulated cultures was similar in
ABPA and non-ABPA CF patients and was decreased
compared to non-atopic controls. However, in Asp f2y
f3yf4-stimulated cultures, the frequency of IL-4q
CD3q T-cells was significantly increased in ABPA CF
patients compared to non-ABPA CF patients (Fig. 5b).
This suggests that there is an increased frequency of
Aspergillus-specific Th2 CD4q T-cells in ABPA com-
pared to non-ABPA CF patients.
3.3. BALT immune response in ABPA
Since the immune response to Aspergillus antigens
originates in the bronchoalveolar lymphoid-associated
tissue (BALT), investigators have examined bronchoal-
veolar immunity. Analysis of the cells obtained from
bronchoalveolar lavage fluid (BALF) in ABPA reveals
an admixture of alveolar macrophages, eosinophils and
lymphocytes similar to that found in asthma
w44,45,73,74x. Eosinophil infiltration predominates, both
in BALF and lung tissue, as is evident on lung biopsy
w75x. In addition, eosinophils are activated and have
released their mediators, such as major basic protein.
Thus, eosinophils are a major effector cell causing
inflammation. Lymphocytes found in BALF are com-
posed of T-, B- and NK cells. The T-cells are an
admixture of CD4q and CD8q T-cells, approximately
in a 2:1 ratio. Interestingly, we have observed increased
CD23q NK cells and CD23qCD4q T-cells obtained
from BALF of ABPA patients, indicating in vivo IL-4
stimulation w1x. Recently, in preliminary studies,
increased in vivo CD23q expression (;10%) on
CD4q T-cells in CF ABPA patients has been observed.
The significance of CD23q T-cells is probably T-cell
CD23 and B-cell CD21 T::B ligand–counterligand inter-
action and augmentation of IgE synthesis. Similarly,
CD23q NK cells are an important source of sCD23
andyor NK CD23::B cell CD21 interaction, increasing
immunoblast IgE secretion. Recently, we have observed
induction of CD23qCD69qCD4q T-cells in Aspergil-
lus-stimulated cultures of CF ABPA patients (unpubli-
shed results). In addition, the expression of CD23 is
extremely elevated on addition of IL-4. The role of this
CD4q T-cell subpopulation in ABPA is unknown, but
is under study.
3.4. B-cell responses in ABPA
In ABPA, extremely elevated total serum IgE concen-
trations and elevated IgE anti-Aspergillus antibodies are
characteristic of ABPA. There appear to be quantitative,
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Fig. 3. IL-4 induction of CD23q molecules on CD20q and on CD86q CD20q B-cells. ABPA CF patients had significantly increased number
of CD23 molecules (a) per B-cell and (b) per CD86q B-cell on day 0 compared to non-ABPA CF patients (P-0.01) and non-atopic control
patients (P-0.01). Following IL-4 stimulation, ABPA CF patients had a significantly increased rate of CD23q expression (a) per B-cell and
(b) per CD86q B-cell compared to non-ABPA CF (P-0.01) and non-atopic control patients (P-0.01). Data presented as mean"S.E. (from
Knutsen et al. w66x).
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Fig. 4. IL-13 induction of CD23q molecules on CD20q and on CD86q CD20q B-cells. Following IL-13 stimulation, ABPA CF patients had
no significantly increased rate of CD23q expression (a) per B-cell and (b0 per CD86q B-cell compared to non-ABPA CF and non-atopic control
patients (P-0.01). Data presented as mean"S.E. (from Knutsen et al. w66x).
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Fig. 5. Th1 and Th2 CD3q T cells. (a) Following PMA and ionomycin stimulation, ABPA CF patients had comparable percentages of IFN-g
and IL-4 CD3q T-cells compared to non-ABPA CF patients. However, both ABPA and non-ABPA CF patients had significantly decreased
percentages of IFN-g CD3q T-cells compared to normal control subjects (P-0.001, P-0.001 respectively). (b) Following tetanus toxoid and
Asp f2y3y4 stimulation, both ABPA and non-ABPA CF patients had significantly decreased IFN-g CD3q T-cells compared to normal control
subjects (P-0.05, P-0.05, respectively) but not different from each other. However, ABPA CF patients had significantly increased Asp f2y3y4-
stimulated IL-4 CD3q T-cells compared to non-ABPA CF patients and normal control subjects (P-0.01, P-0.01, respectively). Data presented
as mean"S.E. (from Knutsen et al. w66x).
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Table 2
In vitro IgE synthesis by B-cells of patients with cystic fibrosis and allergic bronchopulmonary aspergillosis
Patient group Serum IgE IgE (pgyml)
(IUyml)
B cells alone Autologous BqT
Preformed Net
Net
ABPA (5) 4870"836 1754"595 1980"617 675"393
STyPPT positive (9) 291"56 566"205 220"112 90"35
STyPPT negative (13) 58"22 167"66 13"10 140"98
Control (23) – 355"58 76"34 139"39
P (ANOVA) -0.01 -0.01 -0.01 -0.05
From Knutsen et al. w33x. Abbreviations: ST, Aspergillus prick skin test; PPT, Aspergillus precipitins. The number of individuals studied is in
parentheses. Purified-B cells were cultured for 10 days. The net B-cell IgE synthesis was calculated from IgE concentrations of day 10 minus
preformed day 0 cultures. Preformed day 0 IgE concentration determined by lysis of day 0 B-cells. Data are presented as mean"S.E.M. P values
were determined by ANOVA. P-0.05 comparing ABPA vs. STyPPT positive and STyPPT negative using the post hoc Sheffe test.
and perhaps qualitative, differences of the B-cell IgE
antibody responses in ABPA compared to Aspergillus-
sensitized non-ABPA atopic patients. The heightened
total and specific anti-Aspergillus IgE antibody
responses have been described by several groups
w4,10,76–80x. In ABPA, there are also increased
amounts of IgG and IgA anti-Aspergillus antibodies,
reflective of the Th2 humoral vs. Th1 cellular response
to Aspergillus antigens w81–88x. Although other Asper-
gillus-exposed groups develop IgE, IgG and IgA anti-
Aspergillus antibodies, there is a quantitative increase in
IgE anti-Aspergillus antibodies in ABPA patients. As
observed in Table 2, it was previously reported that B-
cells obtained from patients with ABPA spontaneously
synthesize increased amounts of IgE in vitro compared
to Aspergillus-sensitized non-ABPA patients groups,
indicating in vivo activation of IgE immunoblasts w33x.
In recent studies w66x, we have observed increased
CD23q CD86q B-cells in ABPA that probably
accounts for this previous observation and for this hyper-
IgE state w65x. Furthermore, Greenberger and Patterson
w77x demonstrated that specific anti-Aspergillus fumiga-
tus IgE and IgA antibodies are produced within BALT.
In contrast, IgG anti-Aspergillus antibodies obtained
from BAL fluid were predominantly exudative, derived
from the peripheral systemic lymphoid system. Slavin
et al. w89x demonstrated lymphoid follicles that stained
with anti-IgE in a lung biopsy of a patient with ABPA,
indicating in vivo IgE-bearing B-cells and immunob-
lasts. Greenberger and Patterson w77x further demonstrat-
ed that anti-Aspergillus IgE antibodies comprised only
a small fraction of the total IgE in the peripheral
lymphoid system. This implies that the CD4q Th2 T-
cells have traveled to the systemic immune system and
have activated other clones of B-cells, in addition to
those with Aspergillus specificity.
3.5. IL-4 receptor (IL-4R)
As a potential mechanism for increased B-cell IgE
synthesis and secretion, mutations of IL-4 receptor alpha
chain (IL-4Ra) were evaluated in collaboration with Dr
Talal Chatila. Mutations or polymorphism of IL-4Ra
have been identified in atopic individuals with elevated
IgE levels w40–42x. These polymorphisms increase IL-
4 and IL-4R interactions, resulting in a gain-of-function
of IL-4Ra that promotes B-cell IgE isotope switching.
Subsequently, seven mutations have been identified that
result in increased IL-4R activity w40,90,91x. In addition,
increased IL-4 activity would result in increased expres-
sion of other receptors, including CD23 and CD86 on
B-cells, eosinophils and NK cells, VLA-4 on eosinophils
and T-cells, VCAM on endothelial cells, CCR-3, CCR-
4 and eotaxin secretion (Fig. 1). In preliminary studies,
homozygous mutations of IL-4Ra chain in 2y2 ABPA
patients and heterozygous mutations in 3y5 atopic
patients and 2y5 non-atopic control patients have been
reported. However, increased sensitivity to IL-4 stimu-
lation was observed in ABPA and atopic patients with
IL-4Ra chain mutations and wild type. IL-4R is a
heterodimer, consisting of IL-4Ra chain and the com-
mon gamma chain (Cg) w46–48x. The IL-13R is also a
heterodimer, consisting of IL-4Ra and IL-13Ra chains.
IL-4 stimulates both the IL-4R and the IL-13R receptors,
whereas both IL-4 and IL-13 stimulate the IL-4ayIL-
13Ra receptor. IL-13, like IL-4, increases CD23 expres-
sion, IgE isotype switching and IgE synthesis. However,
IL-13 does not activate and skew Th2 responses. There
is evidence that IL-4Ra and IL-13Ra interact with the
Janus kinase 1 (Jak-1), whereas the Cg chain interacts
with Jak-3. Upon IL-4 stimulation, IL-4a and Cg chains
undergo phosphorylation by Jak-1 and Jak-3. After IL-
13 stimulation, the IL-13Ra chain is phosphorylated by
Jak-1. Phosphotyrosines in the IL-4Ra and IL-13Ra
serve as docking sites for the SH2 domains of the signal
transducer and activator of transcription (STAT6) mol-
ecule. STAT6 is subsequently phosphorylated by the Jak
kinases, when it is then released as a dimer and
translocates to the nucleus activating IL-4 and IL-13
responsive transcription. Our studies demonstrating
increased CD23 expression with IL-4 stimulation sug-
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gest that other mutations or polymorphisms of the IL-
4Ra, IL-13a, Jak-1 or STAT6 pathway may exist.
3.6. Eosinophils and mast cells in ABPA
The effector cells responsible for the allergic inflam-
matory responses in ABPA are predominantly mast cells
and eosinophils. In our model, when Aspergillus anti-
gens cross-link IgE bound to mast cells, mast cells
release a variety of mediators, such as histamine, leu-
kotrienes and PAF, which induce bronchial smooth-
muscle contraction and vascular permeability w1x. A
number of mast cell cytokines, such as leukotriene B4
and PAF, are chemoattractant for eosinophils. In addi-
tion, chemokines, such as eotaxin, RANTES and MCP-
3, derived from a variety of cell types, such as epithelial
and phagocytic cells, induce eosinophil chemotaxis and
activation w43–45,92x. Basophil hyperreactivity with
increased histamine release also has been reported in
ABPA, probably due to IL-4 stimulation w93x. Th2
CD4q T-cells secrete the cytokines IL-3 and IL-5 that
promote bone marrow maturation of eosinophils and
activation of eosinophils w74,94–98x. Furthermore, IL-4
induces expression of VCAM-1 on vascular endothelial
cells and its ligand VLA-4 on T-cells and eosinophils.
Recent studies have demonstrated selective expression
of the eotaxin receptor, chemokine receptor 3 (CCR3),
on eosinophils, basophils, and Th2 T-cells, and CCR3
expression is up-regulated by IL-4 polarizing conditions
w99,100x. Thus, both chemotactic and cell-surface adhe-
sion molecules promote recruitment of Th2 T-cells and
eosinophils within the allergic inflammatory site
w44,45,101,102x. Eosinophils possess Fc receptors for
IgE, IgG and IgA, and IL-4 also induces increased
expression of the low-affinity IgE receptor CD23 on
eosinophils w74x. In addition, IL-4 and IL-5 induce Fc
receptors for IgA w74,103x. In ABPA, significant
amounts of Aspergillus-specific IgA antibodies are pro-
duced within BALT and are present within the bronchial
mucus. Thus, both IgE and IgA anti-Aspergillus anti-
bodies bind to their Fc receptors on eosinophils and
trigger mediator release when they engage allergen
w74,104x. When eosinophil-bound IgE, IgA and IgG are
cross-linked by Aspergillus antigens, the eosinophils are
triggered to secrete inflammatory mediators, such as
major basic protein and eosinophil-derived neurotoxin
w74x.
3.7. HLA-DR restriction in ABPA
Chauhan et al. w35x investigated whether there is
unique TCR recognition (T-cell epitopes), TCR-Vb
restriction or HLA-class II restriction that would pro-
mote enhanced Th2 responses. Analysis of T-cell epitope
mapping has revealed that there are three immunodom-
inant regions of the Asp f1 protein in ABPA patients
that are recognized by TCR w35x. Their findings were
similar to that found in other allergen models. O’Hehir
and Lamb’s group has evaluated T-cell responses to
purified house dust mite allergens. In their model, T-cell
clones were generated from atopic and non-atopic indi-
viduals w105x. Significantly, the T-cell clones from non-
atopic individuals proliferated in response to allergen
stimulation, but did not support IgE synthesis, whereas
the T-cell clone from atopic patients did. Furthermore,
TCR epitope mapping studies revealed a limited number
of epitopes reacting with TCR w106,107x, TCR Vb
restriction or usage w108,109x, and HLA class II restric-
tion w109x. Four major Vb chains, Vb 3, 6, 13 and 14,
react to Asp f1. This will allow for evaluation of whether
mutations of the epitope might alter the T-cell cytokine
andyor lymphoproliferative responses for potential
immunotherapy of ABPA. Recently, Chauhan and co-
workers w35,36x identified that there is HLA-DR2 (split
into HLA-DR15 and DR16) and HLA-DR5 restriction
in patients with ABPA. Furthermore, within HLA-DR2
and HLA-DR5, there are restricted genotypes. In partic-
ular, HLA-DRB1*1501 and 1503 were reported to pro-
vide high relative risk. On the other hand, 40–44% of
non-ABPA atopic Aspergillus-sensitive individuals have
the HLA-DR2 andyor DR5. Further studies indicated
that the presence of HLA-DQ2 (especially DQB1*0201)
provided protection from the development of ABPA.
These results are similar to those found with purified
house dust mite allergens w110–112x. Thus, certain
genotypes of HLA-DR2 and DR5 may be necessary, but
not sufficient to cause ABPA. Furthermore, Chauhan et
al. w36x demonstrated that Asp fl allergen has low
affinity of binding to HLA-DR. This is consistent with
Th2 T-cell response previously reported by others, in
that strong antigen HLA-DR-Ag-TCR affinity binding
favors a Th1 cellular response and low-affinity binding
favors a Th2 humoral response w111–115x.
3.8. CFTR mutations in ABPA
Since ABPA is found in highest incidence in atopic
CF patients, Miller et al. w116x examined CFTR muta-
tions in asthmatic ABPA patients. Six of 11 patients had
mutations of the CFTR gene. Clearly, there was
increased frequency of heterozygous mutations of the
CFTR gene in these asthmatic patients. It has been
hypothesized that, in CF, the abnormal mucus promotes
the trapping of Aspergillus spores within the bronchial
airway, permitting and perhaps promoting Aspergillus
mycelia growth. The significance of the heterozygous
CFTR mutation in asthmatic patients is unclear as to
the mucus properties of these asthmatics. Thus, the
abnormal mucus may allow increased Aspergillus colo-
nization within the bronchial airway of CF and asth-
matics, and, in a genetically susceptible individual,
stimulate a Th2 T-cell response and subsequent ABPA.
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Table 3
Summary of immunopathogenesis of ABPA
≠ Th2 CD4q T-cell response to Aspergillus fumigatus
BALT mucosal immune response
≠ IL-4, IL-13, IL-5
≠ IgE total and anti-Aspergillus antibodies
≠ IgA and IgG anti-Aspergillus antibodies
≠ Eosinophil BALT and peripheral
≠ VLA-4 and VCAM integrins
Migration of eosinophils and lymphocytes into inflammatory lesions
≠ Th2 Af-specific
HLA-DR2 (DR15, DR16) and HLA-DR5 restriction
Genotype restriction (DRB1*1501 and 1503)
Low-affinity binding
Presence of HLA-DQ2 is protective (DQB1*0201)
TCR-Vb restriction (Vb3, b6, b13, b14)
≠ IL-4 activity
≠ IL-4Ra homozygous b chain mutations (preliminary data)
Mast cell degranulation
Basophil hyperreactivity
≠ sCD25 during ABPA flares
≠ T suppressor function
Anergy to A. fumigatus by DTH
CFTR heterozygous mutations
? effect on mucus properties
In summary, a quantitative increased Th2 CD4q T-
cell response to Aspergillus in both the BALT and
systemic immune systems characterize ABPA (Table 3).
Perhaps key in the immunopathogenesis is that the
BALT is exposed to high levels of Aspergillus allergens,
perhaps because of abnormal mucus properties due to
CFTR mutations. Antigen presentation to T-cells is
characterized by HLA-DR 2 and DR5 restriction of low-
affinity antigen binding. In addition, there is restricted
TCR-Vb usage. Thus, there is an immunogenetic sus-
ceptibility to develop ABPA, which resides within the
HLA-DR-Ag-TCR signaling of the T-cells toward a Th2
CD4q T-cell response. In addition, there may increase
sensitivity of T-cells, B-cells, NK cells and eosinophils
to IL-4 stimulation due to mutations of IL-4Ra andyor
the JakySTAT pathway, accounting for the allergic
inflammatory response to Aspergillus. This leads to a
positive feedback amplification loop of Th2 CD4q T-
cells™IL-4 synthesis™CD23qCD86q B-cells. If the
hypothesis is confirmed, it would suggest therapeutic
targeting at IL-4, IL-4R andyor CD86. The results of
these studies have significance for the atopic state in
general: they suggest that the airway changes observed
in ABPA are an example of allergen-induced allergic
inflammation airway remodeling observed in asthmatic
patients.
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